Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000950170-25-019942·AN2 Therapeutics, Inc.
Schedule 13G ownership disclosure
AN2 Therapeutics, Inc.
Common Stock, par value $0.00001 per share · CUSIP: 037326105
Event date: 2024-12-31
- Filing-level shares
- 1,893,132
- Percent of class
- 6.2%
- Eric Easom
Shares: 1,893,132 · Class: 6.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-019942
- Form type
- SCHEDULE 13G/A
- Filer
- AN2 Therapeutics, Inc.
- CIK
- CIK 1880438
- Filed
- Feb 13, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership